# A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

> **NCT03629756** · PHASE1 · COMPLETED · sponsor: **Arcus Biosciences, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Bladder Cancer
- Ovarian Cancer
- Endometrial Cancer
- Merkel Cell Carcinoma
- GastroEsophageal Cancer
- Renal Cell Carcinoma
- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Etrumadenant
- **DRUG:** Zimberelimab

## Key facts

- **NCT ID:** NCT03629756
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-24
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-09-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03629756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03629756, "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03629756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*